Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
This article sets out the Jount Council for Practitioners/Cosmetic Practice Standards Authority position regarding responsible prescribing of POMs used in aesthetic practice. The guidance accords with that set down by the majority of the healthcare professional regulators and by the Royal Pharmaceutical Society. With regard to delegated prescribing, prescribers are reminded that patients remain under the oversight of the prescriber, requiring that the prescriber must be familiar with the patient through an initial face to face consultation and diagnostic assessment of the patient's suitability for treatment. This applies to the routine/planned/repeat administration of medicines that are used specifically for cosmetic purposes, such as botulinum toxins, injected local anaesthetic or topical adrenaline, and the emergency use of medicines such as hyaluronidase. Prescribers are also reminded of their obligation to address the existence of competing interests and to place the needs of the patient first and be transparent about their actions.
Journal of Aesthetic Nursing – Mark Allen Group
Published: Sep 2, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.